HUP0200819A3 - Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk - Google Patents
Medicaments containing inhibitors of cell-volume regulated human kinase h-sgkInfo
- Publication number
- HUP0200819A3 HUP0200819A3 HU0200819A HUP0200819A HUP0200819A3 HU P0200819 A3 HUP0200819 A3 HU P0200819A3 HU 0200819 A HU0200819 A HU 0200819A HU P0200819 A HUP0200819 A HU P0200819A HU P0200819 A3 HUP0200819 A3 HU P0200819A3
- Authority
- HU
- Hungary
- Prior art keywords
- sgk
- cell
- medicaments containing
- human kinase
- containing inhibitors
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19917990A DE19917990A1 (en) | 1999-04-20 | 1999-04-20 | Medicament containing inhibitors of cell volume regulated human kinase h-sgk |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0200819A2 HUP0200819A2 (en) | 2002-07-29 |
HUP0200819A3 true HUP0200819A3 (en) | 2009-08-28 |
Family
ID=7905297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0200819A HUP0200819A3 (en) | 1999-04-20 | 2000-04-19 | Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1171131A1 (en) |
JP (1) | JP2002542196A (en) |
KR (1) | KR100718900B1 (en) |
CN (1) | CN1351496A (en) |
AU (1) | AU779941B2 (en) |
BR (1) | BR0009914A (en) |
CA (1) | CA2369078A1 (en) |
CZ (1) | CZ20013778A3 (en) |
DE (1) | DE19917990A1 (en) |
HU (1) | HUP0200819A3 (en) |
MX (1) | MXPA01010588A (en) |
NO (1) | NO20015054L (en) |
PL (1) | PL198427B1 (en) |
RU (1) | RU2288718C9 (en) |
SK (1) | SK14972001A3 (en) |
UA (1) | UA79066C2 (en) |
WO (1) | WO2000062781A1 (en) |
ZA (1) | ZA200108610B (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10042137A1 (en) * | 2000-08-28 | 2002-03-14 | Florian Lang | sgk2 and sgk3 as diagnostic and therapeutic targets |
DE10113876A1 (en) * | 2001-03-21 | 2002-09-26 | Eberhard Karls Uni Medizinisch | Quantitative diagnosis of genetically related hypertension, by correlating blood pressure with overexpression or modification of human sgk family proteins |
WO2002087417A2 (en) * | 2001-04-27 | 2002-11-07 | Cold Spring Harbor Laboratory | Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity |
DE10149393A1 (en) * | 2001-09-28 | 2003-04-24 | Florian Lang | Detecting the expression of serum and glucocorticoid-dependent kinase-1 (sgk1), for diagnosing coagulative diseases, diabetes, tumors, diabetes and autoimmune diseases, comprises using an antibody against sgk1 |
DE10225844A1 (en) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk and nedd as diagnostic and therapeutic targets |
DE10305212A1 (en) * | 2003-02-07 | 2004-08-19 | Florian Prof. Dr.med. Lang | Use of the sgk gene family for the diagnosis and therapy of cataracts and glaucoma |
MXPA05009292A (en) * | 2003-03-03 | 2006-03-21 | Florian Lang | Sgk1 as diagnostic and therapeutic target. |
WO2004084889A1 (en) * | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
DE10346913A1 (en) * | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | acylhydrazone |
WO2005084702A1 (en) * | 2004-03-02 | 2005-09-15 | Hokkaido Technology Licensing Office Co., Ltd. | Agent for preventing and treating organ fibrosis |
CN1964705A (en) * | 2004-03-11 | 2007-05-16 | 默克专利有限公司 | Methods for interfering with fibrosis |
KR20070015148A (en) * | 2004-03-11 | 2007-02-01 | 메르크 파텐트 게엠베하 | Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases |
US20090136920A1 (en) * | 2004-04-30 | 2009-05-28 | Stefan Golz | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) |
WO2005118832A2 (en) * | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl) |
DE102004030987A1 (en) | 2004-06-26 | 2006-01-12 | Merck Patent Gmbh | Ortho-substituted (3-hydroxyphenyl) -acetic acid benzylidene hydrazides |
MX2007001155A (en) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Methods, systems, and computer program products for providing presence gateway functionality in a telecommunications network. |
DE102005001053A1 (en) * | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Square acid derivatives |
DE102005015255A1 (en) * | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | New acylhydrazide compounds are signal transduction kinase inhibitor, useful for treating and/or preventing diseases, e.g. diabetes, adiposity, metabolic syndrome, cancer and tumor cells |
DE102005035742A1 (en) * | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | New cyclobut-3-ene-1,2-dione derivatives are kinase inhibitors useful for treating e.g. cancer, hypertension, diabetes, glaucoma and bacterial infections |
DE102005039541A1 (en) * | 2005-08-22 | 2007-03-22 | Merck Patent Gmbh | 3-oxo-indazol-square acid derivatives |
DE102007002717A1 (en) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclic indazole derivatives |
DE102007022565A1 (en) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclic indazole derivatives |
EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
DE102008010362A1 (en) | 2008-02-18 | 2009-08-20 | Florian Prof. Dr. Lang | Sgk1 as a therapeutic and diagnostic target for viral diseases |
DE102008010363A1 (en) | 2008-02-18 | 2009-08-20 | Lang, Florian, Prof. Dr.med. | Sgk1 as a therapeutic and diagnostic target for carcinomatous diseases |
DE102008010361A1 (en) | 2008-02-18 | 2009-08-20 | Merck Patent Gmbh | sgk1 inhibitors for the prophylaxis and / or therapy of viral diseases and / or carcinomas |
DE102008029072A1 (en) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis |
DE102008038222A1 (en) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carboxylic acid derivatives |
DE102008038220A1 (en) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | oxadiazole |
DE102008038221A1 (en) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-azaindole derivatives |
DE102008059133A1 (en) | 2008-11-26 | 2010-05-27 | Merck Patent Gmbh | Difluorophenyl diacylhydrazide derivatives |
US8802099B2 (en) | 2010-11-10 | 2014-08-12 | National Jewish Health | Methods to treat allergic conditions |
CN107875153A (en) * | 2017-11-16 | 2018-04-06 | 上海壹志医药科技有限公司 | The medicinal usage of Des-N-methylchelerythrine |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5373501A (en) * | 1976-12-11 | 1978-06-30 | Kitasato Inst | Novel antibiotics amm2282 and process for preparing same |
US5242397A (en) * | 1989-06-20 | 1993-09-07 | Cedars-Sinai Medical Center | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty |
US5137912A (en) * | 1991-01-28 | 1992-08-11 | National Science Council Of Republic Of China | Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug |
GB9325395D0 (en) * | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
US5874464A (en) * | 1995-01-13 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Conformationally constrained diacylglycerol analogues |
WO1997007081A2 (en) * | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
DE69708629T2 (en) * | 1996-05-30 | 2002-08-01 | Aventis Pharmaceuticals Inc., Bridgewater | ALKYLOXYAMINE SUBSTITUTED FLUORENONE DERIVATIVES AND THEIR USE AS PROTEIN KINASE-C INHIBITORS |
EP0887081B1 (en) * | 1997-06-27 | 2003-04-23 | Smithkline Beecham Corporation | Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy |
EP0889127A1 (en) * | 1997-07-01 | 1999-01-07 | Smithkline Beecham Corporation | Serine/threonine protein kinase (H-SGK2) |
CO4940430A1 (en) * | 1997-07-07 | 2000-07-24 | Novartis Ag | POLYCLIC COMPOUNDS CONTAINING HYDROGENATED STAUROSPORIN WITH CONVENIENT PHARMACOLOGICAL PROPERTIES AND AN INHIBITING EFFECT ON THE GROWTH OF TUMOR CELLS |
-
1999
- 1999-04-20 DE DE19917990A patent/DE19917990A1/en not_active Ceased
-
2000
- 2000-04-19 HU HU0200819A patent/HUP0200819A3/en unknown
- 2000-04-19 KR KR1020017013336A patent/KR100718900B1/en not_active IP Right Cessation
- 2000-04-19 CN CN00807959A patent/CN1351496A/en active Pending
- 2000-04-19 MX MXPA01010588A patent/MXPA01010588A/en not_active Application Discontinuation
- 2000-04-19 BR BR0009914-7A patent/BR0009914A/en not_active Application Discontinuation
- 2000-04-19 UA UA2001117896A patent/UA79066C2/en unknown
- 2000-04-19 AU AU42972/00A patent/AU779941B2/en not_active Ceased
- 2000-04-19 WO PCT/EP2000/003578 patent/WO2000062781A1/en not_active Application Discontinuation
- 2000-04-19 CZ CZ20013778A patent/CZ20013778A3/en unknown
- 2000-04-19 PL PL352547A patent/PL198427B1/en unknown
- 2000-04-19 CA CA002369078A patent/CA2369078A1/en not_active Abandoned
- 2000-04-19 EP EP00922655A patent/EP1171131A1/en not_active Withdrawn
- 2000-04-19 SK SK1497-2001A patent/SK14972001A3/en unknown
- 2000-04-19 RU RU2001131351/15A patent/RU2288718C9/en not_active IP Right Cessation
- 2000-04-19 JP JP2000611917A patent/JP2002542196A/en active Pending
-
2001
- 2001-10-17 NO NO20015054A patent/NO20015054L/en not_active Application Discontinuation
- 2001-10-19 ZA ZA200108610A patent/ZA200108610B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE19917990A1 (en) | 2000-11-02 |
ZA200108610B (en) | 2002-01-02 |
SK14972001A3 (en) | 2002-06-04 |
AU779941B2 (en) | 2005-02-17 |
PL198427B1 (en) | 2008-06-30 |
NO20015054D0 (en) | 2001-10-17 |
KR20020012172A (en) | 2002-02-15 |
UA79066C2 (en) | 2007-05-25 |
AU4297200A (en) | 2000-11-02 |
HUP0200819A2 (en) | 2002-07-29 |
PL352547A1 (en) | 2003-08-25 |
CA2369078A1 (en) | 2000-10-26 |
KR100718900B1 (en) | 2007-05-17 |
NO20015054L (en) | 2001-12-14 |
EP1171131A1 (en) | 2002-01-16 |
CN1351496A (en) | 2002-05-29 |
BR0009914A (en) | 2002-01-08 |
WO2000062781A1 (en) | 2000-10-26 |
JP2002542196A (en) | 2002-12-10 |
MXPA01010588A (en) | 2004-09-06 |
RU2288718C9 (en) | 2008-04-27 |
RU2288718C2 (en) | 2006-12-10 |
CZ20013778A3 (en) | 2002-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0200819A3 (en) | Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk | |
IL147217A0 (en) | New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain | |
HUP0301005A3 (en) | Pirrolotriazine inhibitors of kinases pharmaceutical compositions containing them and their use | |
HUP0201261A2 (en) | Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them | |
HUP0202897A3 (en) | Diaminothiazoles and their use for inhibiting protein kinases and pharmaceutical compositions containing them | |
IL148719A0 (en) | Kinase inhibitors as therapeutic agents | |
HUP0203323A3 (en) | Tyrosine kinase inhibitors and pharmaceutical compositions containing them | |
HUP0402236A3 (en) | Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof | |
HUP9801877A3 (en) | Medicaments containing tetrahydrofuryl-sulphonamide-derivative as inhibitors of aspartyl-proteases | |
HUP0104379A3 (en) | New crystalline form of omeprazole and medicament containing it | |
IL145907A0 (en) | Use of glucosylceramide synthesis inhibitors in therapy | |
HUP0202319A3 (en) | Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain | |
HUP0202794A3 (en) | Oligonucleotides for inhibiting the expression of human eg5 | |
IL151890A0 (en) | Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain | |
PL356769A1 (en) | Novel heterocyclic compounds and salts thereof and medicinal use of the same | |
HUP0300402A3 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them | |
IL151765A0 (en) | Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain | |
HUP0201405A3 (en) | Pharmaceutical composition for therapeutic use of melatonin | |
PL350850A1 (en) | Method of providing cosmetic/medical therapy | |
AU7402201A (en) | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | |
HUP0200993A3 (en) | Thio-oxindole derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them | |
HUP0203900A3 (en) | Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments | |
GB9906808D0 (en) | Formulation for treatment of pain | |
AU2001240885A1 (en) | Use of glucosylceramide synthesis inhibitors in brain cancer therapy | |
GB0024517D0 (en) | Use of medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |